Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | TECH | Common Stock | Options Exercise | $91.8K | +4K | +10.93% | $22.95 | 40.6K | May 14, 2024 | Direct | |
transaction | TECH | Common Stock | Sale | -$335K | -4K | -9.85% | $83.84 | 36.6K | May 14, 2024 | Direct | F1 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | TECH | Stock Options (Right to Buy) | Options Exercise | $0 | -4K | -25% | $0.00 | 12K | May 14, 2024 | Common Stock | 4K | $22.95 | Direct | |
holding | TECH | Stock Options (Right to Buy) | 17K | May 14, 2024 | Common Stock | 17K | $21.84 | Direct | ||||||
holding | TECH | Stock Options (Right to Buy) | 15.9K | May 14, 2024 | Common Stock | 15.9K | $25.30 | Direct | ||||||
holding | TECH | Stock Options (Right to Buy) | 12.5K | May 14, 2024 | Common Stock | 12.5K | $31.26 | Direct | ||||||
holding | TECH | Stock Options (Right to Buy) | 7.59K | May 14, 2024 | Common Stock | 7.59K | $44.96 | Direct | ||||||
holding | TECH | Stock Options (Right to Buy) | 8.04K | May 14, 2024 | Common Stock | 8.04K | $50.41 | Direct | ||||||
holding | TECH | Stock Options (Right to Buy) | 6.03K | May 14, 2024 | Common Stock | 6.03K | $63.92 | Direct | ||||||
holding | TECH | Stock Options (Right to Buy) | 2.53K | May 14, 2024 | Common Stock | 2.53K | $128.81 | Direct | ||||||
holding | TECH | Stock Options (Right to Buy) | 3.46K | May 14, 2024 | Common Stock | 3.46K | $73.94 | Direct | ||||||
holding | TECH | Stock Options (Right to Buy) | 3.94K | May 14, 2024 | Common Stock | 3.94K | $61.51 | Direct | F2 |
Id | Content |
---|---|
F1 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from 83.55 to 83.94, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
F2 | The option vests on the earlier of the one year anniversary of the grant date (10/26/2023) or the date of Bio-Techne's 2024 annual meeting of shareholders. |